Status:

NOT_YET_RECRUITING

PET-MRI of Reward System in Parkinson's Disease With RBD

Lead Sponsor:

University Hospital, Clermont-Ferrand

Conditions:

Parkinson's Disease (PD)

Eligibility:

All Genders

45-80 years

Phase:

NA

Brief Summary

Impulse control disorders (ICDs) are frequently observed in Parkinson's disease (PD) and can have a major functional impact on the quality of life of both the patient and their entourage. The primary ...

Eligibility Criteria

Inclusion

  • Patients aged 45 to 80 years
  • Patients diagnosed with idiopathic Parkinson's disease (PD) according to the Movement Disorder Society criteria
  • Disease duration between 3 and 7 years
  • Patients receiving chronic dopaminergic treatment including levodopa for at least one year to avoid tolerance issues during acute levodopa administration
  • Ability to cooperate and understand, allowing strict compliance with the conditions set forth in the protocol
  • Patients affiliated with or beneficiaries of a social security system
  • Volunteer patients capable of providing informed consent to participate in the research

Exclusion

  • Patients suffering from neurological disorders other than idiopathic Parkinson's disease (PD)
  • Patients with severe depression (Beck Depression Inventory \\\[20\] (BDI) score \> 30), apathy (Starkstein scale \\\[21\] score ≥ 14), cognitive impairment (Montreal Cognitive Assessment \\\[MoCA\] \\\[22\] score \< 25), or impulse control disorders (QUIP - Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease \\\[23\], score ≥ 1)
  • Patients with severe motor symptoms: patients with an MDS-UPDRS III score \> 45 will be excluded to avoid severe discomfort or interfering tremor (tremor item ≥ 3 in any body part) in the OFF state during PET-MRI acquisition. Patients with severe dyskinesias will also be excluded due to technical issues related to movement
  • Patients under guardianship, curatorship, deprived of liberty, or under legal protection
  • Pregnant or breastfeeding women
  • Patients with contraindications to PET-MRI (e.g., those with pacemakers or insulin pumps, metallic prostheses or intracerebral clips, claustrophobia, neurosensorial stimulators or implantable defibrillators, cochlear implants, ferromagnetic ocular or cerebral foreign bodies near nervous structures, uncooperative or agitated patients, neurosurgical ventriculoperitoneal shunts, dental appliances)
  • Refusal to participate

Key Trial Info

Start Date :

January 1 2026

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

January 1 2029

Estimated Enrollment :

44 Patients enrolled

Trial Details

Trial ID

NCT07213219

Start Date

January 1 2026

End Date

January 1 2029

Last Update

December 3 2025

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

CHU Clermont-Ferrand, Clermont-Ferrand,

Clermont-Ferrand, France, 63000

2

CH Le Puy en Velay

Le Puy-en-Velay, France